Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jadenu is a prescription oral iron chelator containing deferasirox. It treats chronic iron overload from blood transfusions in patients age 2 and older and selected chronic iron overload in non-transfusion-dependent thalassemia syndromes in patients age 10 and older.
read more about jadenu ...Deferasirox is an oral chelator with high affinity for ferric iron. Two deferasirox molecules bind one ferric iron atom, forming a complex that is eliminated mainly through the feces. Treatment lowers excess body iron over time.
Jadenu is used for documented chronic transfusional iron overload from age 2. It is also used from age 10 for non-transfusion-dependent thalassemia syndromes when liver iron concentration is at least 5 mg iron per gram of dry weight and serum ferritin is greater than 300 mcg per L.
For transfusional iron overload with estimated glomerular filtration rate above 60 mL per minute per 1.73 square meters, the starting dose is 14 mg per kg once daily. For qualifying non-transfusion-dependent thalassemia, the starting dose is 7 mg per kg once daily. Tablets or Sprinkle granules are taken on an empty stomach or with a light meal.
Jadenu carries boxed warnings for renal failure, hepatic failure, and gastrointestinal hemorrhage. Other serious concerns include bone marrow suppression, severe skin reactions, hypersensitivity, gastrointestinal ulceration, overchelation, and auditory or ocular toxicity. Treatment is contraindicated when estimated glomerular filtration rate is below 40 mL per minute per 1.73 square meters.
Jadenu treats selected forms of chronic iron overload from transfusions or non-transfusion-dependent thalassemia.
The labeled starting dose is 14 mg per kg once daily when kidney function meets the treatment criteria.
The labeled starting dose is 7 mg per kg once daily.
Yes. The boxed warnings concern renal failure, hepatic failure, and gastrointestinal hemorrhage.
Deferasirox: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a606002.html. Date Accessed October 5, 2026.
Deferasirox Reduces Iron Overload Significantly in Nontransfusion-Dependent Thalassemia: 1-Year Results From a Prospective, Randomized, Double-Blind, Placebo-Controlled Study. https://pubmed.ncbi.nlm.nih.gov/22589472/. Date Accessed October 5, 2026.
JADENU (Deferasirox) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1. Date Accessed October 5, 2026.
JADENU (Deferasirox) Prescribing Information. https://www.novartis.com/us-en/sites/novartis_us/files/jadenu.pdf. Date Accessed October 5, 2026.
Randomized Phase II Trial of Deferasirox (Exjade, ICL670), a Once-Daily, Orally-Administered Iron Chelator, in Comparison to Deferoxamine in Thalassemia Patients With Transfusional Iron Overload. https://pubmed.ncbi.nlm.nih.gov/16818273/. Date Accessed October 5, 2026.